Early-stage cancer drugs testing across six California centers
Official title: Phase 1 and 2 Molecular and Clinical Pharmacodynamic Trials ETCTN
Funded at Beckman Research Institute/city of Hope · NIH-11499388 · Data updated 2026-11-12
Researchers at six leading cancer centers are teaming up to test new cancer therapies in early-stage clinical trials to help patients with cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beckman Research Institute/city of Hope NIH-funded |
| Lab location | 1 site (Duarte, United States) |
| Project start | March 28, 2014 |
| Project end | February 28, 2027 |
| Funding year | 2026 |
| Award (this year) | $1,915,725 |
| NIH project number | 3UM1CA186717-09S1 |
| Project ID | NIH-11499388 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with specific cancer types evaluated at the participating centers who meet trial inclusion criteria and are profile-matched for early-phase drug testing.
✕Less likely to help
Patients not eligible for the trials or whose cancer does not align with the tested agents may not receive direct benefits.
What this research studies
This program brings together experts from City of Hope, USC, UCD, Stanford, University of Chicago, and Case Western to run initial human studies of promising cancer drugs. The team will use molecular pharmacology, pharmacokinetics, pharmacodynamics, and bioinformatics to understand how experimental treatments behave in patients. The goal is to quickly identify which new therapies show potential for larger trials while ensuring safety and scientific rigor. Patients may participate if they fit the trial criteria and are treated at participating centers.
Why it matters
Potential benefit: If successful, patients could gain access to cutting-edge therapies earlier in the disease course or in early-phase trials that inform future treatment options.
How similar studies have gone: Prior early-phase cancer trials at ETCTN centers have generated promising signals and guided subsequent development of targeted therapies.
Where this research is happening
-
Beckman Research Institute/city of Hope
Duarte, United States Active
Researchers
- Principal investigator: Danilov, Alexey V. — Beckman Research Institute/city of Hope
- Study coordinator: Danilov, Alexey V.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.